Efficacy and safety results of micellar water, cream and serum for rosacea in comparison to a control group

Guertler, Anne; Jøntvedt, Nora Marie; Clanner‐Engelshofen, Benjamin M.; Cappello, Christian; Sager, Angelika; Reinholz, Markus

doi:10.1111/jocd.13591

Cited by 12 publications

(18 citation statements)

References 25 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Excessive oil content is occlusive and may thus aggravate complaints in rosacea [131], but appropriate skin care can provide a fundamental contribution in alleviating symptoms such as tension, burning, or discomfort [129,131,132,138].…”

Section: ↑↑ 100 %mentioning

confidence: 99%

S2k guideline: Rosacea

Clanner‐Engelshofen¹,

Bernhard²,

Dargatz³

et al. 2022

J Deutsche Derma Gesell

Self Cite

View full text Add to dashboard Cite

This updated and upgraded S2k guideline deals with the diagnosis and treatment of rosacea, which is a common, chronic inflammatory skin disease mostly affecting the face. Initially, rosacea is characterized by recurrent erythema, telangiectasia and flushing. Later, the inflammatory component predominates, with persistent erythema with follicular papules, papulopustules and pustules. The development of phyma, which usually occurs on the acral localizations, is the most severe manifestation. For the treatment of rosacea, the interdisciplinary guideline committee, with representatives of the German Dermatological Society (DDG), the Professional Association of German Dermatologists (BVDD), the German Opthalmological Society (DOG), the Society for Dermopharmacy (GD), the Swiss Society for Dermatology and Venereology (SGDV) and the German Rosacea Aid e. V., recommends the avoidance of trigger factors and topical applications of metronidazole, azelaic acid or ivermectin. For

show abstract

Section: ↑↑ 100 %mentioning

confidence: 99%

S2k guideline: Rosacea

Clanner‐Engelshofen¹,

Bernhard²,

Dargatz³

et al. 2022

J Deutsche Derma Gesell

Self Cite

View full text Add to dashboard Cite

show abstract

“…The product documentation should be available to dermatologists and pharmacists. Guertler and colleagues evaluated the efficacy and safety of micellar water, cream, and serum in 50 Caucasian patients with rosacea and observed a significant reduction of facial erythema and rosacea-associated symptoms [26]. Baldwin and colleagues assessed the efficacy and tolerability of a tinted daily SPF-30 facial moisturizer on rosacea-prone skin in 33 females with mild to moderate rosacea and nontransient erythema in terms of coverage of skin redness and feelings of skin dryness and tightness/tension, reporting that the moisturizer did improve the skin appearance of rosacea-prone patients [27].…”

Section: Skin Care and Cosmetic Treatmentsmentioning

confidence: 99%

Rosacea Treatment: Review and Update

Zhang

Tang

Wang

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Rosacea is a chronic and inflammatory skin disease characterized by flushing, nontransient erythema, papules/pustules, telangiectasia, and phymatous changes. Secondary manifestations, such as itching, burning, or stinging, are often observed in patients with rosacea. In 2017, a phenotype-based approach for diagnosis and classification was recommended. With the update of the diagnosis and classification of rosacea, treatment options for patients with rosacea have attracted the attention of dermatologists. Here, we summarize the latest advances in rosacea treatment, including skin care and cosmetic treatments, topical therapies, oral therapies, laser- and light-based therapies, injection therapies, treatments for specific types of rosacea, treatments for systemic comorbidities, and combination therapies. The impact of the phenotype-based approach on rosacea treatment and future directions are also discussed.

show abstract

“…Among 2461 potential studies, 206 satisfied the inclusion criteria (eFigure in the Supplement). Among included trials, 163 (79%) were for acne and 43 (21%) were for rosacea. Rosacea RCTs were more likely to include at least 1 PROM (67% [n = 29 of 43]) compared with acne RCTs…”

Section: Resultsmentioning

confidence: 99%

“… Among included trials, 163 (79%) were for acne and 43 (21%) were for rosacea. Rosacea RCTs were more likely to include at least 1 PROM (67% [n = 29 of 43]) compared with acne RCTs…”

Section: Resultsmentioning

confidence: 99%

Use of Patient-Reported Outcomes in Acne Vulgaris and Rosacea Clinical Trials From 2011 to 2021

Miller

Tong

et al. 2022

JAMA Dermatol

View full text Add to dashboard Cite

ImportanceAcne and rosacea have substantial implications for quality of life, and it is therefore important to ensure the patient’s voice is being captured in pivotal randomized clinical trials (RCTs). Although patient-reported outcome measures (PROMs) are a valuable tool to capture the patient perspective, little is known about use of PROMs in RCTs on acne and rosacea.ObjectiveTo characterize the use of PROMs in RCTs on acne and rosacea.Evidence ReviewA systematic literature search was conducted using the search terms acne vulgaris and rosacea in the following databases: MEDLINE through PubMed, Embase, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. A modified search hedge for RCTs from the McGill Library was applied. All phase 2, 3, and 4 RCTs published between December 31, 2011, through December 31, 2021, that evaluated the efficacy and safety of therapies for acne and rosacea vs any comparator were eligible for inclusion.FindingsA total of 2461 publications describing RCTs were identified, of which 206 RCTs met the inclusion criteria (163 trials [79%] on acne and 43 [21%] on rosacea). At least 1 PROM was used in 53% of trials (110) included; PROM use was more common in rosacea RCTs (67% [n = 29]) compared with acne RCTs (50% [n = 81]). At least 1 dermatology-specific (13% [n = 27]) or disease-specific (14% [n = 28]) PROM was included in the RCTs analyzed. Only 7% of trials (14) included a PROM as a primary outcome measure. There was no statistically significant increase in PROM inclusion over the study period (11 of 21 trials in 2011 vs 5 of 12 trials in 2021).Conclusions and RelevanceIn this systematic review, PROMs were included in approximately one-half of acne and rosacea RCTs performed over the study period. In addition, PROMs were rarely used as a primary outcome measure, and inclusion of PROMs has not increased substantially over the past 10 years. Increasing use of PROMs in RCTs can ensure that the patient’s perspective is captured during the development of new treatments for acne and rosacea.

show abstract

Efficacy and safety results of micellar water, cream and serum for rosacea in comparison to a control group

Cited by 12 publications

References 25 publications

S2k guideline: Rosacea

S2k guideline: Rosacea

Rosacea Treatment: Review and Update

Use of Patient-Reported Outcomes in Acne Vulgaris and Rosacea Clinical Trials From 2011 to 2021

Contact Info

Product

Resources

About